New treatment might have the potential to slow or stop the progression of Parkinson’s disease. VALBY, 12-Sep-2018 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) begins clinical development of yet another potential new treatment of Parkinson’s disease with the enrollment of the … Read the full press release
Posted in Denmark, Healthcare, Pharma & Biotech
Tagged antibody, brain_cells, Genmab, Lundbeck, Parkinson's, Parkinson's disease, proteins
Lu AF28996 is the third compound added to Lundbeck’s clinical development pipeline in 2018. VALBY, 28-Jun-2018 — /EuropaWire/ — H. Lundbeck A/S (Lundbeck) again expands its pipeline of clinical development projects with the initiation of a phase I study of a … Read the full press release
DUNDEE, Scotland, 11-Jun-2018 — /EuropaWire/ — A charity trekker whose husband’s life was cut short by Parkinson’s disease has been hailed as an inspiration by University of Dundee researchers developing treatments for the condition. Lyndsey Isaacs visited the University’s School of … Read the full press release
Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones Foliglurax is a first-in-class treatment which entered clinical phase II testing in Parkinson’s … Read the full press release
Posted in Business, Denmark, Netherlands, Pharma & Biotech
Tagged acquisition, Anders Götzsche, dopaminergic, dyskinesia, Foliglurax, H. Lundbeck A/S, Parkinson's, Prexton Therapeutics BV, PTX002331
Researchers have found that excess levels of calcium in brain cells may lead to the formation of toxic clusters that are the hallmark of Parkinson’s disease. CAMBRIDGE, 20-Feb-2018 — /EuropaWire/ — The international team, led by the University of Cambridge, found … Read the full press release
Delft, Netherlands, 24-4-2015 — /EuropaWire/ — Brain stimulation is now being used successfully to combat diseases such as Parkinson’s, chronic depression, pain and tinnitus. By making neurostimulators smaller and more energy efficient, they can be used more effectively and for … Read the full press release
Posted in Education, Electronics & Machinery, Healthcare, Netherlands, Science, Technology
Tagged chronic depression, energy efficient, Marijn van Dongen, neurostimulators, pain, Parkinson's, tinnitus, TU Delft
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
